261 related articles for article (PubMed ID: 28025927)
21. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
22. Medicare's Variation in Out-of-Pocket Costs for Prescriptions: The Irrational Examples of In-Hospital Observation and Home Infusion.
Wright B; Dusetzina SB; Upchurch G
J Am Geriatr Soc; 2018 Dec; 66(12):2249-2253. PubMed ID: 30264858
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of older adults who meet the annual prescription drug expenditure threshold for medicare medication therapy management programs.
Daniel GW; Malone DC
J Manag Care Pharm; 2007 Mar; 13(2):142-54. PubMed ID: 17330975
[TBL] [Abstract][Full Text] [Related]
25. Financial Hardship from Purchasing Medications for Senior Citizens Before and After the Medicare Modernization Act of 2003 and the Patient Protection and Affordable Care Act of 2010: Findings from 1998, 2001, and 2015.
Olson AW; Schommer JC; Mott DA; Brown LM
J Manag Care Spec Pharm; 2016 Oct; 22(10):1150-8. PubMed ID: 27668563
[TBL] [Abstract][Full Text] [Related]
26. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080
[TBL] [Abstract][Full Text] [Related]
27. Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.
Pauly NJ; Talbert JC; Brown J
J Manag Care Spec Pharm; 2016 Jun; 22(6):741-51. PubMed ID: 27231801
[TBL] [Abstract][Full Text] [Related]
28. Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes.
Glynn A; Hernandez I; Roberts ET
Health Serv Res; 2022 Oct; 57(5):1136-1144. PubMed ID: 35430735
[TBL] [Abstract][Full Text] [Related]
29. Improving Comprehensive Medication Review Acceptance by Using a Standardized Recruitment Script: A Randomized Control Trial.
Miguel A; Hall A; Liu W; Garrett J; Ballew A; Yang TH; Segal R
J Manag Care Spec Pharm; 2017 Jan; 23(1):13-21. PubMed ID: 28025924
[TBL] [Abstract][Full Text] [Related]
30. Out-of-pocket health spending by poor and near-poor elderly Medicare beneficiaries.
Gross DJ; Alecxih L; Gibson MJ; Corea J; Caplan C; Brangan N
Health Serv Res; 1999 Apr; 34(1 Pt 2):241-54. PubMed ID: 10199672
[TBL] [Abstract][Full Text] [Related]
31. Federal and Individual Spending on the 10 Costliest Medications in Medicare Part D from 2011 to 2015.
Watanabe JH; Chau DL; Hirsch JD
J Am Geriatr Soc; 2018 Aug; 66(8):1621-1624. PubMed ID: 29972589
[TBL] [Abstract][Full Text] [Related]
32. Association Between Prescription Drug Insurance and Health Care Utilization Among Medicare Beneficiaries.
Alexander GC; Schiman C; Kaestner R
Med Care Res Rev; 2018 Apr; 75(2):153-174. PubMed ID: 29148319
[TBL] [Abstract][Full Text] [Related]
33. Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act.
Narasimmaraj PR; Oseran A; Tale A; Xu J; Essien UR; Kazi DS; Yeh RW; Wadhera RK
J Am Coll Cardiol; 2023 Apr; 81(15):1491-1501. PubMed ID: 37045519
[TBL] [Abstract][Full Text] [Related]
34. Medicare part D after 2 years.
Joyce GF; Goldman DP; Vogt WB; Sun E; Jena AB
Am J Manag Care; 2009 Aug; 15(8):536-44. PubMed ID: 19670957
[TBL] [Abstract][Full Text] [Related]
35. Prescription drug spending and hospital use among Medicare beneficiaries with heart failure.
McGee BT; Higgins MK; Phillips V; Butler J
Res Social Adm Pharm; 2020 Oct; 16(10):1452-1458. PubMed ID: 31953113
[TBL] [Abstract][Full Text] [Related]
36. Beneficiaries with cardiovascular disease and thePart D coverage gap.
Polinski JM; Shrank WH; Glynn RJ; Huskamp HA; Roebuck MC; Schneeweiss S
Circ Cardiovasc Qual Outcomes; 2012 May; 5(3):387-95. PubMed ID: 22511746
[TBL] [Abstract][Full Text] [Related]
37. Has Medicare Part D reduced racial/ethnic disparities in prescription drug use and spending?
Mahmoudi E; Jensen GA
Health Serv Res; 2014 Apr; 49(2):502-25. PubMed ID: 24102408
[TBL] [Abstract][Full Text] [Related]
38. Insurance coverage for prescription drugs: effects on use and expenditures in the Medicare population.
Lillard LA; Rogowski J; Kington R
Med Care; 1999 Sep; 37(9):926-36. PubMed ID: 10493470
[TBL] [Abstract][Full Text] [Related]
39. Per-Prescription Drug Expenditure by Source of Payment and Income Level in the United States, 1997 to 2015.
Tang W; Xie J; Kong F; Malone DC
Value Health; 2019 Aug; 22(8):871-877. PubMed ID: 31426927
[TBL] [Abstract][Full Text] [Related]
40. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
Yeung K; Dusetzina SB; Basu A
JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
